Braxia Scientific Acquires US Mental Health Platform KetaMD.

MANews-(C)2009-2022

Canada-based mental health treatment and research company Braxia Scientific Corp (CSE: BRAX) (OTC: BRAXF) (FSE: 4960) has acquired 100% of the issued and outstanding stock of US-based telemedicine firm KetaMD, Inc, the company sadi.

KetaMD is a US based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments.

KetaMD's end-to-end telemedicine platform, utilizing leading technology, provides access to affordable at-home ketamine treatments for people suffering from depression and related mental health conditions.

Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's psychiatrists and researchers in depression.

KetaMD's innovative technology capabilities provides Braxia the opportunity to offer both patient-centric in-person and digital telehealth ketamine treatments, combined with established clinical research and development capabilities focused on the commercialization and real-world implementation of novel pharmaceuticals.

Braxia plans to further augment tools and capabilities of the KetaMD platform, including planning new clinical trials in the US and leveraging Braxia's growing proprietary patient dataset, with patient outcomes, to support potential future development of digital therapeutics in the management of depression and other related mental health conditions.

KetaMD is currently available in the State of Florida but a roll-out to other key states is planned in 2022.

KetaMD was founded by psychedelic pioneers Zappy Zapolin and Warren Gumpel, along with mindfulness...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT